Pancreatic cancer is chemo-resistant and metastasizes early with an overall five-year survival of ∼8.2%. First-in-class imipridone ONC201 is a small molecule in clinical trials with anti-cancer activity. ONC212, a fluorinated-ONC201 analogue, shows preclinical efficacy in melanoma and hepatocellular-cancer models. We investigated efficacy of ONC201 and ONC212 against pancreatic cancer cell line...

The class VI intermediate filament protein, nestin is reported to be a progenitor cell marker in various tissues. In the present study, we analyzed the expression and roles of nestin in angiogenesis of pancreatic ductal adenocarcinomas, and determined whether nestin is a potential target for inhibiting tumor angiogenesis using a gene silencing str...

UNLABELLED Gemcitabine is currently the standard therapy for pancreatic cancer. However, growing concerns over gemcitabine resistance mean that new combinatory therapies are required to prevent loss of efficacy with prolonged treatment. Here, we suggest that this could be achieved through co-administration of RNA interference agents targeting the ubiquitin ligase ITCH. Stable anti-ITCH siRNA an...

Pancreatic cancer remains as one of the most deadly cancers, and responds poorly to current therapies. The prognosis is extremely poor, with a 5-year survival of less than 5%. Therefore, search for new effective therapeutic drugs is of pivotal need and urgency to improve treatment of this incurable malignancy. Synthetic alkyllysophospholipid analogues (ALPs) constitute a heterogeneous group of ...

Cancer arises from mutations accruing within cancer cells, but the tumor microenvironment (TME) is believed to be a major, often neglected, factor involved in therapy resistance and disease progression. Cancer-associated fibroblasts (CAFs) are prominent key components of TME most types solid tumors. Extensive research over past decade revealed their ability modulate metastasis, angiogenesis, me...

Purpose Transforming growth factor β (TGFβ) is upregulated in many types of tumors and plays important roles tumor microenvironment construction, immune escape, invasion, metastasis. The therapeutic effect antibodies nuclide-conjugated drugs targeting TGFβ has not been ideal. Targeting with small-molecule or peptide carriers labeled diagnostic/therapeutic nuclides a new development direction. T...

Pancreatic cancer is characterized by constitutive activation of the mitogen-activated protein kinase (MAPK) pathway. Mutations of KRAS or BRAF and epigenetic abrogation of DUSP6 contribute synergistically to the constitutive activation of MAPK. Active MAPK induces the expression of a variety of genes that are thought to play roles in malignant phenotypes of pancreatic cancer. By blocking the f...

Pancreatic cancer is the fourth most common cause of cancer-associated death in western countries, where incidence and number deaths are increasing every year. Intrinsic or acquired resistance tumor cells to chemotherapy agents major reason for failure traditional treatment. Several factors implicated this impressive resistance; however, these, it important highlight extensive cellular heteroge...